The best way to make money investing is to know something’s going to pay off before it actually does. But that’s impossible, no one can predict the future, right? Not per se, but occasionally there are early signs, right there for all of us to see, that… Read More

Preparing a company for its public debut on the stock market is a long and arduous process. The numbers need to be checked and checked again, dozens of meetings with potential investors need to be arranged, and a virtual mountain of paperwork needs to be reviewed by regulators. So when… Read More

Companies are sitting on record amounts of cash. Default rates on corporate bonds — even for companies with questionable credit that pay high yields — are plummeting. So why did I just tell my High-Yield Investing subscribers to watch out? #-ad_banner-#There’s a danger lurking… Read More

With the market posting weaker results in recent weeks, an increasing number of stocks are sinking further and further away from their 52-week highs. Finding which stocks deserve to be sold off and which are just victims of a tough market can be a challenge. That’s why it pays to… Read More

Investing in smaller companies can offer individual investors many important advantages. Perhaps the most important of all is that these companies can grow very quickly, since it doesn’t take much for new sales and profits to make a big impact on overall growth. Many stocks with small market capitalizations also… Read More

Bill Clinton flipped a switch and changed the world. On May 1, 2000, the former President instructed the Federal Aviation Administration to turn off the “Selective Availability” option on the Global Positioning System (GPS), which had made the network of satellite signals usable only by high-tech… Read More

The market’s rough patch has recently knocked many stocks from their 52-week highs. Even the companies that are performing well are drifting ever lower, but the companies that have dared to stumble this spring are really taking a beating. One false move and they wake up to a share price … Read More

Finding good stocks to buy is always a challenge, and mutual funds face that challenge just like individual investors. Although many studies find that the average mutual fund lags the market, some funds do have amazing long-term records and it is often a good… Read More

Back in late April, I cautioned that summer trading can be quite tricky, noting that May is a good time to take profits because the market often weakens in June and July. Little did I know that the “summer swoon” would actually start in May. Since hitting a recent peak… Read More

There’s a drama unfolding in the health care field that is as dramatic as the daytime soap operas. Lots of “he said, she said” has been tossed around, and just to add a little spice, a “bete noire” has also appeared on the scene to cause trouble. If this drama plays out a certain way, then shareholders of one or two of the companies involved may see a big windfall. The drama began back in 2006 when little-known Pharmathene (NYSE: PIP) sued Siga Technologies (Nasdaq: SIGA) for damages stemming from a broken business deal. Pharmathene had loaned… Read More

There’s a drama unfolding in the health care field that is as dramatic as the daytime soap operas. Lots of “he said, she said” has been tossed around, and just to add a little spice, a “bete noire” has also appeared on the scene to cause trouble. If this drama plays out a certain way, then shareholders of one or two of the companies involved may see a big windfall. The drama began back in 2006 when little-known Pharmathene (NYSE: PIP) sued Siga Technologies (Nasdaq: SIGA) for damages stemming from a broken business deal. Pharmathene had loaned Siga money to fund research into a vaccination against smallpox. The loan was presumed to be an interim step before the two firms eventually merged. At a minimum, Pharmathene hoped to at least be granted rights to Siga’s drug, known as ST-246. The two firms had even drawn up documents that appear to imply a merger discussion was the eventual expected result. Siga appeared to eventually lose interest in any deal, figuring that it no longer needed Pharmathene’s stronger balance sheet to help fund the… Read More